Oxidant stress, inflammation and atherogenesis

Lupus

Volumn 14, Issue 9, 2005, Pages 760-764

  Davì, Giovanni ^a   Falco, A ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherogenesis; Inflammation; Oxidant stress; Platelet activation

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CYSTATHIONINE BETA SYNTHASE; ISOPROSTANE DERIVATIVE; PHOSPHOLIPID ANTIBODY; REACTIVE OXYGEN METABOLITE; THROMBOXANE;

ANALYTIC METHOD; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FATTY ACID SYNTHESIS; HOMOCYSTINURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; INFLAMMATION; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PALEARCTIC; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; INFLAMMATION; LIPID PEROXIDATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; OBESITY; OXIDANTS; OXIDATIVE STRESS; RISK FACTORS;

EID: 26244441533     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2216oa     Document Type: Review

References (15)

1. 2- isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004; 128: 149-163.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
3. Wang TJ, Nam BH, Wilson PW et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002; 22: 1662-1667.
4. Ridker PM, Cannon CP, Morrow D et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
5. Koenig W. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Int J Cardiol 2005; 98: 199-206.
6. Davì G, Chiarelli F, Santilli F et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003; 107: 3199-3203.
7. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-592.
8. Cipollone F, Mezzetti A, Porreca E et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
9. Davì G, Guagnano MT, Ciabattoni G et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-2014.
10. Davì G, Di Minno G, Coppola A et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001; 104: 1124-1128.
11. Ferro D, Pittoni V, Quintarelli C et al. Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation 1997; 95: 1425-1432.
12. Iuliano L, Pratico D, Ferro D et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997; 90: 3931-3935.
13. Ferro D, Basili S, Roccaforte S et al. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2689-2697.
14. Pratico D, Ferro D, Iuliano L et al. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 1999; 93: 3401-3407.
15. Ferro D, Pignatelli P, Loffredo L et al. Soluble CD154 plasma levels in patients with systemic lupus erythematosus: modulation by antiphospholipid antibodies. Arthritis Rheum 2004; 50: 1693-1694.